The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy.

類似資料

• I-123 imaging for the prediction of I-131 therapy for recurrent differentiated thyroid cancer, RDTC, when I-131 tracer is negative but raised thyroglobulin, Tg
  著者:: Britton, K, 等
  出版事項: (1999)
• The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.
  著者:: Siddiqi, A, 等
  出版事項: (2001)
• Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
  著者:: Mukherjee, J, 等
  出版事項: (2001)
• Sequelae and survivorship in patients treated with (131)I-MIBG therapy.
  著者:: Sze, W, 等
  出版事項: (2013)
• Sequelae and survivorship in patients treated with 131 I-MIBG therapy
  著者:: Sze, W, 等
  出版事項: (2013)